Serbin M, Mansfield C, Leach CA, Yonan C, Klepitskaya O, Sheehan M, Donnelly A. Do patients' experiences with side effects affect their preferences for adjunctive Parkinson's disease treatments? Poster presented at the 8th European Academy of Neurology Congress; June 25, 2022. Vienna, Austria. [abstract] Eur J Neurol. 2022 Jun; 29(Suppl 1):446.
Mangel A, Lothman K. Commentary: emergence of a new paradigm in understanding the cardiovascular system: pulse synchronized contractions. Cardiovasc Pharm Open Access. 2017;6(5):220. doi: 10.4172/2329-6607.1000220
Raspa M, Sacco P, Candrilli SD, Bishop E, Petrillo J. Validity of a condition specific outcome measure for fragile X syndrome: the Aberrant Behaviour Checklist-utility index. J Intellect Disabil Res. 2016 Sep;60(9):844-55. doi: 10.1111/jir.12264
Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-utility analysis of treatments for advanced non-small cell lung cancer. Am J Pharm Benefits. 2015 Nov;7(6):271-9.
Lopes M, Chulikavit M, Parikh R, Stern L, Liu Z, Rogerio J. Budget impact of everolimus in treating metastatic renal cell carcinoma. Am J Pharm Benefits. 2012;4(Special Issue):sp41-8.
Bray JW, Davis KL, Graver L, Schroeder D, Buck JA, Dilonardo J, Vandivort R. Mental health and substance abuse treatment utilization among individuals served by multiple public agencies in 3 states. J Behav Health Serv Res. 2005 Jan 1;32(3):282-93.